Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026

Company Overview - Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [3]. Upcoming Financial Results - Vericel will report its fourth-quarter and full-year 2025 financial results on February 26, 2026, with a conference call and webcast scheduled for 8:30 a.m. ET [1]. Product Portfolio - The company markets three main products in the United States: - MACI, an autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [3]. - Epicel, a permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [3]. - NexoBrid, a biological orphan product for eschar removal in burn patients, for which Vericel holds exclusive North American rights [3].